Showing results (391-400 of 427) with videos related to
Sort By:
Pageof 43
Contact Dermatitis|March 17, 2021
European Surveillance System on Contact Allergies (ESSCA): Characteristics of patients patch tested and diagnosed with irritant contact dermatitisLaura Loman, Wolfgang Uter, José C Armario-Hita, et al.Communications Medicine|May 17, 2023
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profilesJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.Haematologica|August 8, 2024
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III studyDietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, et al.Journal of Cancer Research and Clinical Oncology|September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registryMaher Hanoun, Leo Ruhnke, Michael Kramer, et al.Leukemia|February 10, 2016
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemiaU Krug, W E Berdel, R P Gale, et al.Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.Haematologica|February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemiaSabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.Pageof 43